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Endocytic trafﬁckingcharacterized by vacuolation in nervous tissue accompanied by neuronal death
and gliosis. Although spongiform degeneration is a hallmark of prion diseases, this pathology is also present
in the brains of patients suffering from Alzheimer’s disease, diffuse Lewy body disease, human
immunodeﬁciency virus (HIV) infection, and Canavan’s spongiform leukodystrophy. The shared outcome
of spongiform degeneration in these diverse diseases suggests that common cellular mechanisms must
underlie the processes of spongiform change and neurodegeneration in the central nervous system.
Immunohistochemical analysis of brain tissues reveals increased ubiquitin immunoreactivity in and around
areas of spongiform change, suggesting the involvement of ubiquitin–proteasome system dysfunction in the
pathogenesis of spongiform neurodegeneration. The link between aberrant ubiquitination and spongiform
neurodegeneration has been strengthened by the discovery that a null mutation in the E3 ubiquitin–protein
ligase mahogunin ring ﬁnger-1 (Mgrn1) causes an autosomal recessively inherited form of spongiform
neurodegeneration in animals. Recent studies have begun to suggest that abnormal ubiquitination may alter
intracellular signaling and cell functions via proteasome-dependent and proteasome-independent mechan-
isms, leading to spongiform degeneration and neuronal cell death. Further elucidation of the pathogenic
pathways involved in spongiform neurodegeneration should facilitate the development of novel rational
therapies for treating prion diseases, HIV infection, and other spongiform degenerative disorders.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Spongiform, or vacuolar, change describes tissue that contains
numerous vacuoles that are round or oval in appearance at the light
microscopic level and up to 50 μm in diameter [1–3]. These vacuoles
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ll rights reserved.organelles such as the nucleus and mitochondria. By electron
microscopy (EM), vacuoles can contain curled fragments of mem-
branes and sometimes a ﬂuffy or granular electron-dense material
(Fig. 1B) [1,4,5]. Intramyelinic vacuoles within white matter corres-
pond with splitting of the myelin layers [6–8]. In addition to vacuolar
change, neural tissue may also exhibit microvacuolation, in which the
neuropil is disrupted by numerous small vacuoles of 2 to 10 μm in
diameter [2,3], or status spongiosus, where irregular cavities appear
surrounded by a meshwork of glia [2,3]. Spongiform encephalopathy
describes a group of diseases that exhibit vacuolar change accom-
panied by neural and/or glial cell death in the central nervous system.
The vacuoles observed in spongiform degeneration are the result of a
speciﬁc disease process and not merely the product of cell loss.
Spongiform pathology is most commonly associated with prion
diseases (Fig. 1A) [1], but also occurs in the brains of patients suffering
from neurodegenerative diseases (Fig. 1A) [3,4,9,10], human immu-
nodeﬁciency virus (HIV) infection [11–16], and metabolic disease [17].
The extent and localization of spongiform change varies depen-
ding on the speciﬁc disease, yet each disorder shares common
pathological features (Table 1). In animals, spongiform degeneration
has been observed in prion disease [1], retrovirus infection (Fig. 1B)
[18–20], and as a consequence of mutation in several different genes
(Fig. 1B) [6,7,21–25]. The vacuolar change observed in animals shares
pathological features with human spongiform encephalopathies, and
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agent or gene mutated (Table 2). Histological comparisons of disease
versus control tissue from both human and animal spongiform
encephalopathies reveals increases in ubiquitinated proteins near
areas of spongiform change [4,9,20,26,27], indicating that aberrant
ubiquitination may be involved in the pathogenesis of spongiform
degeneration.
Ubiquitination of proteins serves as a signal for a variety of cellular
functions (reviewed in [28]). Ubiquitination of a substrate protein
occurs via a cascade of three enzymes (an E1 ubiquitin-activating
enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin–
protein ligase) and is reversible by the action of a deubiquitinating
enzyme (DUB). Additional rounds of ubiquitination can result in the
formation of a polyubiquitin chain through one of the seven internal
lysine residues of ubiquitin. The number and location of attachment
sites of mono- or polyubiquitin on a substrate protein comprises the
ubiquitin signal [28,29]. A major proteolytic system in the cell is the
ubiquitin–proteasome system (UPS), which degrades a majority of
cytoplasmic proteins. Substrate proteins processed by the UPS are
typically taggedwith a polyubiquitin chain linked through Lys 48; four
ubiquitins linked via K48 is the minimal signal recognized by the
proteasome for substrate degradation [30]. In addition to substrate
proteins, the UPS also regulates levels of the ubiquitinating enzymes. A
number of E3 ligases are degraded via the UPS [31–33], thus
modulating levels of ubiquitination in the cell. Since the ubiquitinating
machinery is regulated by the proteasome, proteasomal impairment
can result in aberrant ubiquitination of proteins in addition to
accumulation of ubiquitinated proteasome substrates [34–39]. Protea-
some-independent ubiquitin signals, such as monoubiquitination and
K29- and K63-linked polyubiquitination, regulate endocytic trafﬁck-
ing, lysosomal protein degradation, DNA repair, protein aggregation
and autophagic degradation, and protein localization [29,35,40–46].
Because of its versatility as a signal, changes in the ubiquitination
of proteins can affect a wide range of cellular processes. This suggests
that the pathogenesis of spongiform degeneration may result from
dysfunction of common pathways regulated by ubiquitination in
spongiform disorders with different etiologies. This review willFig. 1. Spongiform degeneration in humans and animals is characterized by vacuolar change
right, CJD prion plaque surrounded by vacuoles1, counterstainedwith hematoxylin and eosin;
counterstained with hematoxylin and eosin; and AD medial temporal lobe3, counterstaine
brainstem from mouse infected with FrCasE retrovirus4, immunostained with anti-FrCa
immunostained with anti-glial ﬁbrillary acidic protein; cortex from mahogany (Atrnmg3J/A
brainstem vacuole from mahogany (Atrnmg3J/Atrnmg3J) mouse5. All images reprinted with p
from Elsevier. 2Reprinted from the American Journal of Pathology [1], copyright ©1972, wi
Archives of Neurology [3], copyright ©1987, with permission from the American Medical As
copyright ©2004, with permission from the American Society for Biochemistry and Moleculexamine the evidence implicating several cellular pathways in
spongiform degeneration and explore how these processes are
connected and maintained via ubiquitination of proteins. Recent
studies indicate that aberrant ubiquitination mediates the pathogen-
esis of spongiform change and cell death by altering normal cell
function and intracellular signaling.
2. UPS dysfunction accompanies vacuolar change in spongiform
encephalopathies of both humans and animals
2.1. Prion diseases
The transmissible spongiform encephalopathies (TSEs) refer to a
number of fatal diseases that occur in man and animals that result in
widespread vacuolation, neurodegeneration, and gliosis of the central
nervous system (reviewed in [1,47]). TSEs are characterized by
progressive motor difﬁculties, such as unsteady gait, ataxia, and
tremor, accompanied by cognitive and sensory defects [1,47,48].
Human TSEs include Creutzfeldt–Jakob disease (CJD), Gerstmann–
Sträussler–Scheinker disease (GSS), kuru, and fatal familial insomnia
(FFI) [1,47,48]. Animal TSEs include scrapie, bovine spongiform
encephalopathy (BSE), chronic wasting disease, feline spongiform
encephalopathy, and transmissible mink encephalopathy [1,47].
Spongiform areas in TSE tissues are typiﬁed by degenerating neurons
that appear swollen and are associated with intracellular and
extracellular membrane-bounded vacuoles containing accumulations
of curled membrane fragments or other granular material [1,5]. The
TSEs are known as prion diseases since prion protein (PrP) appears to
be the transmissible agent in these encephalopathies, because
accumulation of a disease-related conformer of PrP in the brain tissue
of affected organisms occurs along with spongiform pathology
[26,49,50]. Prion plaques, reminiscent of amyloid plaques observed
in Alzheimer’s disease (AD), are sometimes seen in the cerebellum
(Fig. 1A) and other brain areas, consisting of ﬁbrils that radiate out
from a central core, giving a stellate appearance [3,26]. In advanced
stages of these disorders, secondary spongiform change of the white
matter may be seen [1]. Experimental models of prion diseases arein the central nervous system. (A) Spongiform degeneration in human diseases. Left to
CJD cerebral cortex2, counterstained with hematoxylin and eosin; kuru cerebral cortex2,
d with hematoxylin and eosin. (B) Spongiform degeneration in rodents. Left to right,
sE surface glycoprotein; cortex from Mgrn1 null (Mgrn1md-nc/Mgrn1md-nc) mouse5,
trnmg3J) mouse5, immunostained with anti-glial ﬁbrillary acidic protein; and EM of a
ermission: 1Reprinted from Lancet Neurology [47], copyright ©2005, with permission
th permission from the American Society for Investigative Pathology. 3Reprinted from
sociation. All Rights reserved. 4Reprinted from the Journal of Biological Chemistry [84],
ar Biology. 5Reprinted from Science [22], copyright ©2003, with permission from AAAS.
Table 1
Spongiform degeneration in human diseases is accompanied by changes in ubiquitination
Disease CNS location of spongiform change Increased
ubiquitination
Altered prion
protein
Gliosis Ref (s)
Creutzfeld–Jakob disease Grey matter of cortex, hippocampus, cerebellum, midbrain, thalamus,
brain stem, motor nuclei of spinal cord
Yes Yes Yes [1,2,26,49,50]
Kuru Grey matter of cortex, cerebellum, midbrain, thalamus, brain stem,
motor nuclei of spinal cord
Yes Yes Yes [1,49]
Alzheimer's disease Grey matter of temporal cortex, amygdala Yes Variable Variable [4,26,49,50]
Diffuse Lewy body disease Grey matter of temporal cortex, amygdala Yes No No [4,9,10]
AIDS/HIV infection Grey matter of cortex, amygdala, midbrain, thalamus; white
matter tracts of spinal cord
Yes No Mild [11,13–16,88]
Canavan's spongiform leukodystrophy White matter regions of cortex, midbrain, cerebellum ND ND Yes [17]
ND, not determined.
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tissue from affected animals or humans. The extent of the pathology
observed varies according to the strain of prion and species infected,
but generally is more severe with a shorter latency than that of
naturally occurring TSEs [1,5,47].
The conformational change of normal cellular PrP protein (PrPC,
cellular) into a disease-related structure (PrPSc, scrapie) is thought to
initiate all TSEs. Familial forms of TSEs (GSS, FFI, and familial CJD)
result from mutations in the PrP gene, PRNP, which presumably alter
the tertiary structure of PrP [47,48,51]. In kuru, non-familial CJD, and
all animal prion diseases, infection with or consumption of tissues
containing PrPSc mediates the propagation of PrPSc from PrPC. PrPC is
necessary for disease pathogenesis, since animals or cells that lack
PrPC are resistant to PrPSc infection and fail to propagate prion
infectivity [52–55]. This supports the hypothesis that PrPSc acts as a
template for the misfolding of PrPC in the host’s tissues (reviewed in
[48,56]). This hypothesis is further supported by the observations that
latency to symptom onset is dependent upon PRNP gene dosage
[52,57] and that PRNP null mice carrying a hamster PRNP transgene
are more sensitive to infection with hamster prions than with mouse
prions [57,58].
Immunocytochemical staining of brain tissue from CJD or experi-
mental murine scrapie reveals punctate ubiquitin labeling in and
around areas of spongiform change as well as at the periphery of the
prion plaques [26,27]. Ubiquitination of proteins in brain homoge-
nates from scrapie-infected animals increaseswith disease duration as
measured by enzyme-linked immunosorbent assay, while proteolytic
activity of the proteasome decreases with infection [59]. These
observations are supported by cDNA microarray analysis of mice
infected with a strain of BSE [60], which reveals differential expression
of UPS machinery genes in response to infection, including several
proteasome subunits, E2s, and E3s. PrPC has been shown to be
ubiquitinated and processed by the UPS [39], while PrPSc appears to be
ubiquitinated at late stages of disease when the protein is highly
aggregated [59,61]. These reports indicate that dysfunction of the
proteasome and the subsequent changes in protein ubiquitination
resulting from proteasome impairment play a key role in prion disease
pathogenesis. In addition to the UPS, other cellular pathways likely
contribute to the vacuolation and degeneration of nervous tissue
observed in TSEs. Increases in oxidative stress have been reportedTable 2
Spongiform degeneration and changes in ubiquitination in animals results from infection a
Disease/Mutation CNS location of spongiform change
Scrapie or BSE Grey matter of cerebellum, hypothalamus, medulla
Experimental prion infection Grey matter of cerebellum, hypothalamus, medulla
MoMuLV-infected mouse Grey matter of cerebellum, thalamus, brainstem, motor nuc
Coronavirus-infected mouse Grey matter of cortex, hippocampus, midbrain, brain stem,
Mgrn1md-ncmouse Grey matter of cortex, cerebellum, hippocampus, midbrain,
Mahogany mouse/Zitter rat Grey matter of cortex, cerebellum, midbrain, hypothalamus
ND, not determined.(reviewed in [62]) and there is considerable evidence for aberration in
the proteolytic processing and trafﬁcking of PrPC [49,63–67] and
lysosomal dysfunction in TSEs [27,49,60,68,69]. These processes are
regulated by both proteasome-dependent and -independent ubiquitin
signaling (reviewed in [29,70,71]).
2.2. Non-transmissible neurodegenerative diseases with spongiform
lesions
Progressive neurodegenerative diseases that are not characterized
as TSEs, such as AD and diffuse Lewy body disease (DLBD), also exhibit
spongiform change in deﬁned brain regions [3,4,9,10]. The vacuolar
change in AD and DLBD resembles TSE, although instead of wide-
spread spongiform degeneration, vacuolation and cell loss is restricted
to the medial temporal lobe and the amygdala [3,4,9]. The etiology of
spongiform change is not related to PrPSc, since inoculation of
laboratory animals with affected brain tissue does not result in
transmission of the spongiform pathology, as it would with TSE brain
tissue [4,49]. AD and DLBD brain tissue do not exhibit prion plaques or
the increased PrP immunoreactivity characteristic of TSEs [4,10,26].
Interestingly, recent evidence suggests that PrPC may modulate the
processing of amyloid precursor protein (APP) [72], a protein central to
the etiology of AD, since differential processing of APP contributes to
the production of amyloid deposits that accumulate in AD brains [73].
Similar to TSEs, ubiquitin immunoreactivity is increased in areas
near spongiform degeneration in AD and DLBD brains [9,26], and the
presence of ubiquitin-positive proteinaceous inclusions is positively
correlated with spongiform change [3,9]. These proteinaceous inclu-
sions are characteristic hallmarks of neurodegenerative disease and
are immunoreactive for UPS machinery in addition to ubiquitinated
proteins (reviewed in [74]). Measurement of proteasome activity and
ubiquitinating activity in post-mortem AD [75,76] and Parkinson's
disease [77] brain tissue reveals a signiﬁcant impairment of the UPS in
neurodegenerative diseases. This suggests that, similar to the TSEs,
cell death and spongiform change in these diseases are mediated by
dysfunction of the UPS and altered cellular ubiquitin signaling. Other
similarities between TSEs and neurodegenerative diseases that exhibit
spongiform change include mitochondrial dysfunction and increased
oxidative stress (reviewed in [78,79]), and aberrations in the
endosomal trafﬁcking of proteins (reviewed in [80]), suggesting thend gene mutation
Increased
ubiquitination
Altered prion
protein
Gliosis Ref (s)
Yes Yes Yes [1]
Yes Yes Yes [27]
lei of spinal cord Yes ND Yes [20,82,83]
spinal cord ND ND Yes [8,18]
brain stem ND No Yes [22]
, medulla Yes No Yes [21,22,25,106,107,113,117]
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pendent ubiquitination in the pathogenesis of these diseases.
2.3. Viral-mediated diseases
Spongiformpathology has been reported in central nervous system
tissue from patients with acquired immune deﬁciency syndrome
(AIDS) resulting from HIV infection. Approximately one-ﬁfth of
patients have white matter vacuolation of the spinal cord [12–14],
and a smaller percentage of patients have spongiform change in
cortical areas [11,13,16]. Animal models of HIV infection have more
extensive spongiform pathology. Macaques infected with simian
immunodeﬁciency virus [19] and mice infected with a number of
different retroviruses [8,18,20,81,82] display spongiform degeneration
of either grey orwhitematter and exhibitmotor deﬁcits. Differences in
the localization and extent of spongiform pathology depend upon the
strain of virus used and the cell type(s) that each virus strain infects
[82,83]. The retroviral env protein appears to confer many of the
differences between retroviral strains [84–87]. Experimental manip-
ulation of env to create chimeric envproteins fromdifferent strains of a
mouse retrovirus has revealed that env plays a large role in conferring
neurovirulence [84]. Differential post-translational processing of env
by different cell types in mouse brain affects viral production and
presence of spongiformpathology in a given brain region [86]. Further-
more, transgenic expression of a retroviral env protein by itself is
sufﬁcient to produce spongiformpathology inmice [85], so production
of viral particles per se does not lead to vacuolation and cell death.
Similar to human neurodegenerative diseases, brain areas exhibit-
ing spongiform change display no increase in PrP immunoreactivity
[14], but do show an increase in ubiquitin staining in areas adjacent to
those displaying vacuolar change [20,88]. Infection of mice with the
ts1 strain of Moloney murine leukemia (MoMuLV) retrovirus results
in spongiform degeneration with Lewy body-like cellular inclusions
near areas of spongiform change [20], suggesting that viral infection
may promote protein aggregation. One pathway bywhich retroviruses
could increase protein aggregation is by disrupting UPS function
[34,38,89], similar to the UPS dysfunction and ubiquitin-positive
proteinaceous inclusions associated with neurodegenerative diseases
or the decrease in proteasome activity and presence of ubiquitinated,
aggregated PrPSc observed in TSEs.
The importance of the UPS in the onset of spongiform pathology in
retrovirus infection models is highlighted by a recent study [90],
which examined the effect of different ubiquitin mutant transgenes in
mice infected with ts1 MoMuLV. Transgenic mice that express K48R
ubiquitin, which is capable of forming polyubiquitin chains of any
linkage except K48, survive longer and demonstrate delayed onset of
spongiform pathology compared to wild-type controls after ts1
infection. K63R ubiquitin transgenic mice, whose cells can produce
polyubiquitin chains of any linkage except K63, had similar disease
onset and survival as wild-type ubiquitin mice [90]. These results
suggest that K48-linked polyubiquitination and proteasomal degrada-
tion may be involved in the neurodegenerative process and onset of
spongiform pathology caused by retroviral infection in mice and
humans. However, since elimination of K48-mediated ubiquitination
only delayed and did not prevent spongiform pathology and cell loss,
proteasome-independent ubiquitin signaling may also be utilized by
the cellular processes that contribute to spongiform degeneration.
These processes likely include oxidative stress pathways [91,92], and
functions of the endosome–lysosome system [93–97].
2.4. Spongiform degeneration caused by genetic mutations in humans
and rodents
2.4.1. Aspartoacylase (ASPA)
A humanmetabolic disease, Canavan’s spongiform leukodystrophy
(CD), results in epilepsy and spongiform degeneration of white matter[17]. This disease results from mutation in the aspartoacylase (ASPA,
also known as N-acetyl-L-aspartate aminohydrolase) gene, which
encodes the enzyme responsible for catabolizing N-acetyl-L-aspartate
(NAA). Patients with CD have a buildup of NAA levels in the brain, as
well as increases of NAA in the blood and urine [17]. A rodent form of
CD, the Tremor rat, harbors a spontaneous deletion in ASPA, resulting
in no protein product and increased NAA levels in the brain [23].
Animals exhibit seizure-like activity and spongiform degeneration of
bothwhite and greymatter. Viral gene transfer of ASPA into the Tremor
rat ameliorates the seizures but does not attenuate spongiform
pathology [98], suggesting that vacuolation and degeneration is not a
direct result of increased NAA levels, but possibly signaling pathways
initiated by an increase in NAA. Injection of NAA into rats can produce
seizures [23], and NAA treatment of rat cortical tissue increases
markers for oxidative stress [99], which indicates that neuronal
excitability and oxidative stress signaling contribute to spongiform
degeneration resulting from increased brain NAA levels in CD.
Oxidative stress can modulate a number of cellular pathways,
including gene transcription [100–102], receptor tyrosine kinase
signaling [103], and apoptosis [79,104]. Increased oxidative stress is
known to alter levels of ubiquitination in the cell, as well as change
transcription of several UPS genes [102,105]. Evidence for increased
oxidative stress in CD and the Tremor rat indicates that, in addition to
oxidant signaling pathways, the pathogenesis of spongiform change
may be mediated by changes in ubiquitination.
2.4.2. Attractin (Atrn)
The mahogany mouse [21,106] and the Zitter rat [25,107] both
exhibit spongiform pathology in the brain, body tremor, and changes
in hair color and texture. Both rodents harbor spontaneous mutations
in the attractin (Atrn) gene [21,106,108,109], which encodes a protein
known to regulate coat color in rodents by modulating the
melanocortin signaling pathway [108,110,111]. Signaling via melano-
cortin receptors (Mc1r, Mc3r, and Mc4r) is activated by the ligand α-
melanocyte stimulating hormone (α-MSH) and antagonized by the
inverse agonists Agouti and Agouti-related protein (AgRP) [108,110].
The melanocortin-1 receptor (Mc1r) is a key regulator of pigment
production in hair follicle melanocytes (Fig. 2A), while in brain cells,
body mass and energy homeostasis are regulated via Mc3r and Mc4r
(Fig. 2B) [110].
Atrn is a type I transmembrane protein that acts as an accessory
receptor for Agouti, but not AgRP [108,110,111]. Atrn may exert its
effects in the melanocyte by either extending Agouti inhibition of
Mc1r or via an unknown intracellular signaling cascade. Mutation of
Atrn increases Mc1r signaling, resulting in animals with a darker coat
[108,111]. In the neuron, Atrn may or may not act via an unknown
signaling pathway to modulate Mc3r and Mc4r signaling; mutation
of Atrn results in leaner mice [106,110], but has no signiﬁcant effect
on food intake [106], indicating that Atrn may impact energy
homeostasis signaling, possibly via a downstream effector of Mc3r/
Mc4r or a separate pathway. Atrn may also be involved in cell
survival signaling in the neuron (Fig. 2B), since small interfering
RNA-mediated knockdown of Atrn exacerbates cell death in response
to proteasome or mitochondrial inhibition [112] and one study [109]
suggests that Atrn plays a role in antioxidant signaling via the
extracellular signal-related kinase (ERK)-mediated cell survival
pathway. Zitter rats exhibit age-related neurodegeneration of sub-
stantia nigra dopaminergic neurons [113], which are sensitive to
changes in oxidative stress. These neurons display increased
ubiquitin immunoreactivity and, by EM, abnormalities of mitochon-
dria and endocytic structures [113]. Mahogany mice are also reported
to have mitochondrial abnormalities, including functional deﬁcits
and increased oxidative stress [114]. These ﬁndings indicate that
changes in oxidant signaling, ubiquitination, and endocytic trafﬁck-
ing may all contribute to the spongiform pathology seen in these
mutant mice.
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The link between perturbations in ubiquitination and human
spongiform disorders is especially salient given that loss of the E3
ubiquitin–protein ligase mahogunin ring ﬁnger-1 (Mgrn1) [22,115]
results in progressive spongiform degeneration in mice. Null mutation
of Mgrn1 (Mgrn1md-nc) produces a very similar phenotype to Atrn
mutations, including widespread spongiform degeneration, body
tremor, and dark coat [22,111,116]. Despite the similarity between
Mgrn1md-nc and mahogany phenotypes, biochemical interaction
between Mgrn1 and Atrn has not been established. Atrn protein
levels are normal inMgrn1md-nc mice [22], suggesting that either Atrn
is not a substrate for Mgrn1-mediated ubiquitination or Mgrn1-
mediated ubiquitination of Atrn is a proteasome-independent signal.
Ectopic expression of Atrn does not rescue the Mgrn1 null mutation,
indicating that Mgrn1 function is genetically downstream of Atrn
function [22]. Like Atrn, Mgrn1 is also involved in the melanocortin
signaling pathway, although precisely how Mgrn1 modulates mela-
nocortin receptor signaling is unknown [108,110,111]. One possibility
is that Mgrn1 ubiquitinates the receptors or the downstream effectors
of Mc1r/Mc3r/Mc4r (Fig. 2). Another possibility is that Mgrn1 acts by
ubiquitinating components of an unknown Atrn signaling pathway.
Identiﬁcation of Mgrn1 substrates will help elucidate how Mgrn1
regulates melanocortin signal transduction.
The neurodegeneration resulting from Mgrn1 null mutation
indicates that Mgrn1, like Atrn, may also participate in cell survival
signaling. The widespread vacuolation of brain tissue seen in these
mutant mice is very similar to the pattern observed in TSEs (Table 2).
However, unlike TSEs, the brain tissue of these mice does not exhibit
increased PrP immunoreactivity or protease-resistant PrPSc [22,117].
While PrP is ubiquitinated [39], Mgrn1 does not ubiquitinate PrP [22],
implying that the spongiform degeneration seen in Mgrn1md-nc is not
directly related to prion protein processing and toxicity. We recently
identiﬁed the endosomal sorting protein, tumor susceptibility gene
101 (Tsg101), as a substrate of Mgrn1 E3 ligase [118], associating
dysfunction of endosomal ubiquitin signaling to the pathogenesis of
spongiform change in Mgrn1 null mice. A recent report [114]
describes mitochondrial dysfunction and increased levels of oxidative
stress in theMgrn1md-nc mutant mice, suggesting that oxidative stressFig. 2. Pathways by which Mgrn1-mediated ubiquitination could modulate melanocortin re
hair follicle melanocytes regulates coat color. Activation of Mc1r by the ligandα-MSH results
agonist Agouti promotes the production of the yellow pigment pheomelanin. Mgrn1 may ub
mutant mice. Reduction or loss of Mgrn1-mediated ubiquitination in Mgrn1md-nc mice woul
signaling in hypothalamic neurons modulates insulin sensitivity, regulating energy hom
promoting leaner body mass, and receptor inhibition by AgRP decreases insulin sensitivity, p
the receptors or a downstream target could modulate melanocortin signaling in hypothalam
alter energy homeostasis. The role, if any, of Atrn in hypothalamic melanocortin signaling is
could be modulated by Mgrn1-mediated ubiquitination.may also play a role in the spongiform degeneration observed in
these mice.
3. Proteasome-dependent and -independent ubiquitin signaling
regulates the cellular response to stress and activation of cell
death pathways in spongiform degeneration
3.1. Oxidative stress can inhibit the UPS and contribute to apoptotic cell
death in spongiform degeneration
The aberrant ubiquitination observed in spongiform encephalo-
pathies is indicative of increased cellular stress and dysfunction of the
UPS. Altered ubiquitin signaling can affect a number of cellular
pathways, including those that control cell survival. Programmed cell
death via apoptosis is regulated extensively by the UPS (reviewed in
[119]), since a number of pro- and anti-apoptotic proteins are E3
ligases and their substrates [120–126]. Mitochondria are also
mediators of apoptotic cell death; leakage of mitochondrial proteins
into the cytoplasm is a potent proapoptotic factor (reviewed in [127]).
In addition, mitochondria can be acted upon by signals both inside and
outside the cell to promote or circumvent apoptosis [122,128–130].
Activities of the mitochondria and proteasome are linked, since
inhibition of the proteasome can impair mitochondrial function [131–
134] and mitochondrial impairment leads to decreases in proteasome
activity and upregulation of ubiquitinating enzymes [131,135–138].
Recent evidence indicates that the UPS may be critical for the
maintenance of mitochondrial fusion and ﬁssion machinery [139–
143], which is important for sustaining mitochondrial function and
health. These studies indicate that cross-talk between the mitochon-
dria and UPS regulates apoptotic signaling, so dysfunction of either the
proteasome or mitochondria can initiate mitochondria-mediated
apoptosis and result in cell death [144].
One major source of cellular stress is the oxidation of proteins,
lipids, and nucleic acids by reactive oxygen species (ROS) [145,146].
ROS are generated by the function of the mitochondrial electron
transport chain (ETC), but are normally controlled by cellular
antioxidant systems [147–150]. Increases in cellular ROS, resulting
from impairment of the ETC or loss of protein antioxidants, can easilyceptor regulation of pigment production and energy metabolism. (A) Mc1r signaling in
in production of the black pigment eumelanin, while suppression of Mc1r by the inverse
iquitinate either Mc1r or a downstream target, complementing Agouti signaling in non-
d then stimulate production of eumelanin, producing a darker coat. (B) Mc3r and Mc4r
eostasis and body mass. Receptor activation by α-MSH increases insulin sensitivity,
romoting obesity. In wild-type mice, Mgrn1-mediated ubiquitination of possibly either
ic neurons, while in Mgrn1 null mice, a reduction or loss of Mgrn1 activity could then
unclear, although Atrn may regulate neuronal survival via an unknown pathway, which
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can lead to additional ROS release and initiation of apoptosis [154–
156]. ROS damage to proteins can change protein conformation, alter
enzyme activity, and promote aggregation, necessitating clearance of
damaged proteins by the cell’s proteolytic machinery, usually the UPS
(reviewed in [145,157]). Proteasome activity increases in cells
exposed to mild oxidative stress [138], presumably to handle
increased cellular levels of proteasome substrates. However, high
levels of ROS can oxidatively modify the proteasome, decreasing its
activity [135] and impairing the cell’s ability to remove damaged
proteins, resulting in increases of ubiquitinated and aggregated
proteins [34,38,105,158,159]. In addition to oxidative modiﬁcation of
cellular components, low levels of ROS can serve as an intracellular
signal for kinase activation and gene transcription (reviewed in
[103,160]).
Two models of oxidative stress, manganese superoxide dismutase
(SOD2) and NF-E2-related factor (Nrf2) knockout mice, display
spongiform degeneration [99,156,6,7], highlighting a role for oxidant
signaling and cellular stress in the pathogenesis of spongiform
encephalopathies. SOD2 is a cellular antioxidant and Nrf2 is an
oxidant-responsive transcription factor; knockdown of either of these
proteins impairs cellular defenses against ROS. Furthermore, impair-
ment ofmitochondrial function bymutation of ETC subunits can result
in increased ROS and spongiform degeneration: missense mutation of
the ETC complex III subunit, cytochrome b (CYTB), produces spongi-
form degeneration that resembles CD in dogs, which is accompanied
by impairment of ETC activity and increased ROS [24], while
mutations of the ETC complex IV subunit VIa cause decreases in
mitochondrial function, resulting in neurodegeneration and vacuola-
tion of brain tissue in fruit ﬂies [161]. These examples indicate that
mitochondrial dysfunction and increased ROS can activate pathways
that result in both vacuole formation and cell death.
Increases in markers for oxidative stress and apoptotic cell death
have been reported for prion diseases [62,162], neurodegenerative
diseases [78,79,151], retroviral infection [91,92], a mouse model of CD
[99], Zitter rat [109,163], and both mahogany and Mgrn1md-nc mutant
mice [114]. The role of oxidative stress in promoting spongiform
pathology is emphasized by studies that demonstrate a protective
effect of antioxidants [91,99,163,164]. Treatment of ts-1 MoMuLV-
infected mice with antioxidants delays onset and decreases severity of
spongiform pathology [91]. In addition, antioxidant treatment
decreases apoptotic cell death of cells from Zitter rats [163], SOD2−/−
mice [164], and cells exposed to NAA [99]. Because antioxidants do not
prevent spongiform pathology, oxidative stress signaling is probably
only one of multiple pathways involved in the pathogenesis of
spongiform disorders.
Increased oxidative stress may contribute to spongiform pathol-
ogy via several pathways (Fig. 3). Central to these pathways is the
interdependence of normal function of the proteasome and mito-
chondria. Regardless of the precipitating factor(s) speciﬁc to each of
the spongiform degenerative disorders, once proteasome function is
compromised, mitochondria can become impaired and vice versa
[131–138]. An escalation of cellular stress could occur, since not only
does a decrease in proteasome activity result in protein aggregation
[34,89,158], but protein aggregates have been experimentally shown
to directly inhibit the proteasome [165,166], likely decreasing
proteasome activity further. Increases in ROS can accelerate this
process by promoting both aggregation and proteasomal impairment
[135,137,157,167], contributing to mitochondrial dysfunction and
additional ROS production. This interplay between ROS levels,
mitochondrial dysfunction, proteasome impairment, and protein
aggregation could result in the release of proapoptotic factors from
mitochondria and initiation of apoptosis in neurons, possibly
contributing to the cell death characteristic of spongiform degenera-
tion. Proteasomal dysfunction can also result in aberrant ubiquitina-
tion of proteins, since many ubiquitinating enzymes are regulated byproteasomal degradation [31–34,89,158], which can alter signaling in
many cellular pathways due to changes in the amount, activity,
conformation, and/or localization of proteins regulated by ubiquiti-
nation [29,35,40–46]. Impairment of the proteasome could also
promote a shift to lysosomal/autophagic degradation of proteins in
the cell (reviewed in [168,169]), which is discussed in the following
section.
In TSEs, increased ROS may promote the conversion of PrPC into
PrPSc. Experimental treatment of recombinant PrPC with ROS in vitro
generates oxidized PrP that tends to aggregate, is protease-resistant,
and is capable of templating itself, much like PrPSc [167]. Aggregation
of PrPSc can inhibit the proteasome [166] and PrP aggregation can
activate apoptotic pathways [170]. Oxidative stress signaling via the
ERK pathway is inﬂuenced by both PrPC [53] and Atrn [109]. Loss of
function of either protein via modiﬁcation or mutation results in a
decrease in activated ERK and an increase in apoptotic cell death in
response to oxidative stress [53,109]. PrP null mice have increased
levels of oxidized and ubiquitinated proteins in their brains and
decreased proteasome activity, supporting a role for PrPC in the
cellular regulation of oxidative stress [171] and suggesting that
increases in protein aggregation and decreased proteasome activity
may result from loss of PrPC function in TSEs.
Mitochondrial-mediated apoptosis likely contributes to neurode-
generation in retroviral infection, since overexpression of the
antiapoptotic protein Bcl-2 in mice increases survival and decreases
severity of vacuolar change after ts-1 MoMuLV infection [172]. Atrn
and Mgrn1 may play a more direct role in maintenance of
mitochondrial function, since both Mgrn1md-nc and mahogany mice
exhibit mitochondrial defects in addition to spongiform change [114].
Whether caused by aggregated PrP, virus, or gene mutation, impair-
ment of the UPS and altered ubiquitination in spongiform disorders
could result in mitochondrial dysfunction, release of ROS, increase of
cellular stress, and activation of apoptosis (Fig. 3). However, both
antioxidants and antiapoptotic factors fail to prevent spongiform
degeneration, indicating that other cellular pathways contribute to
cell death and vacuole formation in spongiform pathogenesis.
3.2. UPS dysfunction and increased cellular stress can lead to autophagic
cell death in spongiform disorders
Accumulation of damaged or misfolded proteins that cannot be
processed by the UPS can inhibit proteasome function [165] and
increase cellular stress. Increased levels of cellular stress may alter
ubiquitin signaling, shuttling proteins towards proteasome-indepen-
dent degradation when the UPS is overwhelmed or compromised
[168,173]. We and others have shown that aggregation of proteins into
a specialized structure called the aggresome is mediated by K63-
linked polyubiquitination [37,174]. Sequestration of harmful mole-
cules into an aggresomeminimizes their toxicity and allows the cell to
degrade them in bulk via autophagy (reviewed in [175]). Autophagy
(“self-eating”) is a cellular process whereby cytoplasmic contents,
organelles, or cells are surrounded by membranes (forming an
autophagosome) and delivered to the lysosome for degradation
(reviewed in [176]). Autophagy is activated in response to impairment
of the UPS [173], increased cellular stress [168], and ROS signaling
[177–179]. Autophagymust be tightly regulated by the cell; autophagy
dysfunction [180,181] or prolonged activation of autophagy [182] can
result in autophagic cell death.
The membrane-bound vacuoles observed in spongiform encepha-
lopathies resemble autophagic vacuoles, leading to the hypothesis
that spongiform degeneration results from autophagic cell death
[5,183]. Accumulation of autophagosomes has been reported for CJD
[184], experimental prion disease [183,185], neurodegenerative dis-
orders [186,187], retrovirus infection [20], and in Zitter rat [113]. This
increase in autophagic vacuoles may result from the cell trying to rid
itself of unwanted proteins that are accumulating due to impairment
Fig. 3. Potential mechanisms by which impaired proteasome function and increased oxidative stress in spongiform encephalopathies could result in cell death. Impairment of the
proteasome by protein aggregates, perturbations in ubiquitin signaling, mitochondrial dysfunction and/or increased cellular ROS can result in increases in proteasome substrates and
protein aggregates, alterations in ubiquitination, and apoptotic and/or autophagic cell death via mitochondrial dysfunction and prolonged or aberrant activation of autophagy.
Impairment of mitochondrial function by loss of Mgrn1 or attractin signaling, proteasomal dysfunction, or increased cellular ROS can activate apoptosis, increase cellular ROS levels,
and inhibit the activity of the proteasome. Increased oxidative stress can promote protein aggregation, which can inhibit the proteasome and activate autophagy, impair the functions
of both the mitochondria and the proteasome, and activate apoptosis.
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[104,168,182].
Alterations in activation of autophagy can affect mitochondrial
health, as damaged mitochondria are degraded via autophagy [188].
Ubiquitination of outer mitochondrial membrane components tags
mitochondria with ubiquitin and serves as an autophagic degradation
signal in several cell types [189–191], suggesting that altered
ubiquitinationmay impair the removal of mitochondria by autophagy.
Increases in cellular ROS levels by dysfunctional mitochondria can
damage lysosomes, while impairment of lysosomal function can cause
accumulation of damaged mitochondria from reduced mitochondrial
autophagy (reviewed in [192]). Impairment of proteasomal and
lysosomal degradative pathways can lead to the activation of both
apoptotic and autophagic cell death. In addition, prolonged impair-
ment of the proteasome can result in increased amounts of lipofuscin, a
nondegradable material in lysosomes, which is a marker for lysosomal
dysfunction [193]. As illustrated in Fig. 3, the cell must maintain a
delicate balance between normal functions of the UPS and mitochon-
dria to avoid a buildup of protein aggregates and ROS that can activate
either autophagy or apoptosis. The mitochondrial deﬁcits, increased
oxidative stress, and neurodegeneration observed in mahogany and
Mgrn1md-nc mice [114] likely indicate an upset of this balance.
Although apoptosis and autophagic cell death are different path-
ways that result in cell death, experimental evidence supports bothprocesses contributing to cell death in response to mitochondrial
inhibition and increased ROS [104]. Therefore, neurodegeneration in
spongiform encephalopathies could be the result of activation of both
apoptotic and autophagic cell death pathways. The intracellular and
extracellular vacuoles that characterize spongiform change in grey
matter may originate from incompletely degraded and/or incorrectly
trafﬁcked autophagosomes. Exocytosis of autophagosomes could
contribute to extracellular vacuoles observed in spongiform tissue;
autophagic cell death could also produce extracellular vacuoles, since
undegraded autophagosomes could persist in the neuropil after loss of
the cell that originally contained them. The neurodegeneration and
vacuolation of tissue in spongiform disorders may result from
activation of both apoptotic and autophagic cell death pathways by
proteasome impairment and/or changes in ubiquitination that alter
cellular signaling.
4. Ubiquitin-dependent regulation of intracellular trafﬁcking is
perturbed in spongiform encephalopathies
Trafﬁcking of proteins via the endosomal pathway into the
lysosome comprises a major proteolytic system for membrane
proteins in the cell. In addition to regulating protein levels, endocytic
trafﬁcking also modulates cell surface receptor signaling [70,71,194].
Modiﬁcation of endocytic cargo proteins and the endocytic sorting
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tination) regulates intracellular trafﬁcking [29,43,46,195,196]. Because
the UPS controls the levels of the E3 ligases and DUBs that modulate
endocytic trafﬁcking [35,118,197], the proteasome and lysosome
degradative systems are not independent from one another. Proper
regulation of endocytic sorting is also necessary for autophagic
degradation [198] and cellular health; mutations in endosomal sorting
proteins have been linked to autophagy dysfunction and neurode-
generation [199].
Sorting at the early endosome is accomplished by the endosomal
sorting complexes required for transport (ESCRTs, numbered 0, I, II,
and III). ESCRTs are responsible for directing lysosome-bound cargo
into endosomal intralumenal vesicles (ILVs), forming a structure called
the multivesicular body (MVB) (reviewed in [46]). The MVB/late
endosome can then fuse with the lysosome, delivering the ILVs for
degradation. The MVB can also fuse with the plasma membrane,
releasing the ILVs as exosomes (reviewed in [200]), which may
function in intercellular signaling. Intracellular trafﬁcking and
lysosomal degradation is perturbed in TSEs [26,27,63,68,69,201,202],
AD [80], retroviral infection [93,94,97], cells lacking Mgrn1 [118], and
Zitter rat [113].
PrPC is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein
that primarily is trafﬁcked via the secretory pathway to the plasma
membrane, although populations appear in the endocytic pathway
[65,67] and cytoplasm [39,66]. PrP membrane association is necessary
for prion disease, since mice expressing PrPC missing the GPI anchor
are resistant to clinical disease after infection with scrapie, similar to
PrP knockout mice, despite having high levels of PrPSc and amyloid
plaques in their brains [202]. This indicates PrPSc toxicity is likely
dependent upon its localization to the plasma membrane and/or
endocytic system. The conformational change from PrPC to PrPSc
probably depends upon a number of factors, but abnormal trafﬁcking
to an acidic compartment like the lysosome or MVBmay contribute to
the propagation of protease-resistant PrP [64]. In fact, subcellular
fractionation of scrapie-infected mouse brain [63] reveals that
protease-resistant PrP (PrPSc) accumulates in fractions that also
contain markers for the late endosome and lysosome. This is in
contrast to protease-sensitive PrP (PrPC), which is prevalent in lighter
fractions representing early endosomes [63], indicating that the
conversion of PrPC into PrPSc may alter the trafﬁcking and localization
of PrP in the cell. PrP is known to be released extracellularly via
exosomes [203], so changes in PrP trafﬁcking couldmodify the amount
of prion protein released by exosomes. Altered trafﬁcking of PrPSc
compared to PrPC would also modify intracellular signaling (Fig. 4),
which could contribute to spongiform degeneration [71].
Retroviruses utilize the endosomal sorting machinery for viral
budding (reviewed in [204,205]), perturbing normal endocytic
sorting and trafﬁcking [94,206]. This hijacking of the endocytic
machinery occurs because viral gag proteins can disrupt the
interaction between the ESCRT-0 protein hepatocyte growth factor-
regulated receptor tyrosine kinase substrate (Hrs) and the ESCRT-I
protein, Tsg101 [87,94]. Binding of gag to Tsg101 recruits the
remaining ESCRT proteins to either the MVB or the plasma membrane
for assistance in viral budding [204,206], disrupting sorting of normal
endocytic cargo (Fig. 4). Trafﬁcking defects of endocytic cargo in HIV-
infected cells can be rescued by overexpression of Tsg101 [94],
suggesting that these defects are dependent upon competition
between Hrs and gag for a limited amount of ESCRT-I. The interaction
of retroviral gag proteins with Tsg101 is dependent upon membrane
association and monoubiquitination of gag [93,207]. Alterations in
trafﬁcking by viral infection affect intracellular signaling, and
increased release of exosomes alters intercellular signaling. Increases
in exosome release are observed with retroviral infection, since viral
particles produced at the MVB are then released via exosomes
[96,208]. Extracellular PrP release is increased in cells that are
infected with both PrPSc and MoMuLV [209]. Thus, retroviral infectionalters normal intracellular trafﬁcking and can impair lysosomal
degradation of proteins (Fig. 4).
Our recent identiﬁcation of Tsg101 as a substrate for the E3
ubiquitin ligase Mgrn1 has emphasized the role of endocytic
trafﬁcking in spongiform disorders [118]. Like other sorting proteins,
Tsg101 activity is regulated by ubiquitination [196]. We identiﬁed an
interaction between Mgrn1 and Tsg101 and found that Mgrn1 multi-
monoubiquitinates Tsg101. Small interfering RNA-mediated knock-
down of Mgrn1 results in enlargement of the endocytic compartment
and impairment of the lysosomal degradation of epidermal growth
factor receptor [118]. This indicates that loss of Mgrn1-mediated
ubiquitination of Tsg101 in Mgrn1md-nc mice impairs sorting at the
endosome, preventing endocytic cargo from being degraded by the
lysosome, as well as potentiating receptor signaling (Fig. 4).
Impairment of lysosomal degradation, like proteasomal inhibition,
results in accumulation of proteins destined for degradation [210];
this accumulation increases cellular stress, activating cell death
pathways [104,173]. Impairment of sorting at the endosome also
results in enlargement of endocytic structures [46,69,80,118];
enlarged endosomes could also contribute to the membrane-
bounded vacuoles observed in spongiform diseases in grey matter.
In white matter, perturbation of the endocytic trafﬁcking of myelin
proteins and lipids (reviewed in [211]) could contribute to intramye-
linic vacuoles by interfering with processes necessary for the
maintenance of myelin sheaths. Evidence of endocytic trafﬁcking
dysfunction in TSEs, retroviral infection, and Mgrn1 null mice reveals
that accumulation of lysosomal substrates either through impair-
ment of ESCRT sorting or a shift towards exosome release could play
a role in the pathogenesis of spongiform disorders (Fig. 4). Diversion
of lysosomal substrates from the lysosome can alter intracellular
signaling, which can then activate both apoptotic and autophagic cell
death pathways, likely causing accrual of autophagosomes and
increased cell death, which could result in spongiform change and
neurodegeneration.
5. Conclusions
Spongiform degeneration is the hallmark of prion diseases, yet this
pathology is not speciﬁc to prion protein. Spongiform disorders of
different etiologies share dysfunction of common processes, indicat-
ing that multiple factors act via the same cellular pathways to produce
spongiform pathology. Perturbation of ubiquitination is seen in brain
areas exhibiting spongiform change, suggesting a role for proteasome
dysfunction and altered ubiquitin signaling in these disorders. The
discovery that loss of the E3 ligase Mgrn1 in the Mgrn1md-nc mouse
results in spongiform neurodegeneration supports the idea that
ubiquitination modulates the pathways involved in the onset of
spongiform change. Alterations in ubiquitin signaling modulate
cellular processes by both proteasome-dependent and proteasome-
independent mechanisms. Changes in ubiquitination resulting from
PrPSc, viral infection, environmental factors, aging, or genemutation in
these encephalopathies could impair protein degradation via both the
proteasome and the lysosome. Accumulation of proteasomal and
lysosomal substrates could then increase levels of cellular stress,
activating cell death signaling.
Identiﬁcation of the pathways involved in spongiform neurode-
generation has been aided by a number of geneticmutants that exhibit
spongiform change. Mutations in ASPA, SOD2, Nrf2, and CYTB
emphasize a role for mitochondrial dysfunction and increased ROS
in the onset of spongiform degeneration. Mitochondrial dysfunction
and oxidant signaling are important activators of apoptotic cell death,
which could produce the neurodegeneration seen in spongiform
encephalopathies. Both oxidant and ubiquitin signaling can activate
autophagy, which could be a contributor to spongiform vacuole
formation. Spongiform vacuoles share many characteristics with
autophagosomes and accumulation of autophagic vacuoles has been
Fig. 4. Potential mechanisms by which dysfunction of ubiquitin-mediated endosome-to-lysosome trafﬁcking in spongiform disorders results in abnormal intracellular signaling,
attenuation of lysosomal protein degradation, and impairment of autophagy. Exogenous PrPSc and ligand-bound receptors enter the cell via the endocytic pathway. Receptor
signaling is modulated by lysosomal degradation, which is dependent upon correct ESCRT-mediated sorting of the receptors. PrPC trafﬁcking is disrupted by PrPSc, which canmediate
the conversion of endogenous PrPC into PrPSc in the MVB or other endocytic compartment and accumulates in the MVB/late endosome. Infection of a cell with retroviruses results in
the production of viral gag proteins, which hijack the ESCRT sortingmachinery to aid in viral budding at theMVB or at the plasmamembrane (not shown). Viruses and PrP in theMVB
can be released from the cell via the exosome pathway. Loss of Mgrn1-mediated ubiquitination and viral gag proteins disrupt normal ESCRT sorting of cell surface receptors, which
interferes with receptor degradation by the lysosome, potentiating receptor intracellular signaling. Dysfunction of both the ESCRT sorting machinery and the lysosome impair
degradation of cellular proteins by autophagy.
708 B.R. Whatley et al. / Biochimica et Biophysica Acta 1782 (2008) 700–712reported for a number of spongiform disorders. Autophagy is
dependent upon proper endocytic trafﬁcking and lysosome function,
which is perturbed in prion diseases, AD, and retroviral infection. We
have shown that loss of the E3 ligaseMgrn1 directly impairs endocytic
trafﬁcking through its interaction with the sorting protein Tsg101,
further emphasizing a role for trafﬁcking in the pathogenesis of
spongiform degeneration.
Studies of PrP trafﬁcking and function, retrovirus replication, and
Mgrn1 and Atrn function has increased our understanding of the
processes involved in spongiform degeneration. Further identiﬁcation
of interactors of PrP, Mgrn1, Atrn, and viral proteins will help elucidate
signal cascades that result in cell death and vacuolation in these
disorders. Examination of different spongiform encephalopathies has
illuminated several key cellular pathways that are affected in the
pathogenesis of vacuolar change, which include ubiquitin signaling,
protein degradation, oxidative stress, autophagy, and intracellular
trafﬁcking. More understanding of speciﬁc proteins in the cellular
processes that result in spongiform pathology will enable researchersto identify drug targets to slow down or halt the progression of
spongiform pathology in patients with these disorders.
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